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1 The ERAPharm Consortium
The ERAPharm consortium consists of 14 partners from
eight different countries (seven European countries and
Canada; Table 1). It comprises representatives from the in-
terest groups involved in the registration of pharmaceuti-
cals (i.e. competent authorities, pharmaceutical industry),
scientists from universities and research institutes and two
SMEs (small to medium-sized enterprises). The project is
co-ordinated by ECT Oekotoxikologie GmbH.
2 Project Objectives
The overall objective of ERAPharm is to improve and com-
plement existing knowledge and procedures for the envi-
ronmental risk assessment of human and veterinary phar-
maceuticals. ERAPharm will cover
• fate and exposure assessment,
• effects assessment and
• environmental risk assessment.
An overview of the structure and the work packages of the
project is given in Fig. 1 and Table 2, respectively.
DOI: http://dx.doi.org/10.1065/espr2005.02.238
 Abstract
Triggered by the detection of a large variety of pharmaceuticals in
surface waters, soils and groundwaters across the world (e.g. Halling-
Sørensen et al. 1998, Daughton & Ternes 1999, Jones et al. 2001,
Heberer 2002) and the widespread occurrence of endocrine active
compounds and related effects in the environment (e.g. Purdom et
al. 1994, Tyler et al. 1998, Vethaak et al. 2002), pharmaceuticals in
the environment have become an issue for both the scientific and the
public community. During the last few years, our understanding of
the fate and effects of pharmaceuticals in the environment has pro-
gressed significantly. However, there are still a number of uncertain-
ties concerning the effects of pharmaceuticals on the environment
and the assessment of potential exposure (e.g. Hanisch et al. 2004,
Salomon 2005). These uncertainties will be addressed by the EU-project
'Environmental risk assessment of pharmaceuticals' (ERAPharm). This
project, a specific targeted research project, is carried out within the
priority 'Global change and ecosystems' of the 6th framework pro-
gramme of the European Union. ERAPharm has started on 1st Oc-
tober 2004; the project duration is three years.
Keywords: ERAPharm (environmental risk assessment of pharma-
ceuticals); EU projects; exposure; global change; human and veteri-
nary pharmaceuticals; persistence of chemicals; pharmaceuticals in
surface waters, soils and groundwaters; risk assessment
Table 1: The ERAPharm consortium
EU-Projects ERAPharm
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Based on existing regulatory frameworks on the environmen-
tal risk assessment (ERA) of pharmaceuticals and on the out-
come of previous projects (e.g. the EU-projects ERAVMIS,
POSEIDON and REMPHARMAWATER), ERAPharm will
address the following aspects for both human and veterinary
pharmaceuticals.
2.1 Fate and exposure assessment
ERAPharm will focus on understanding major fate proc-
esses and exposure routes which have so far not been stud-
ied at all or only to a small extent, namely input from pas-
ture animals and through the application of manure and
sewage sludge to land.
The factors and processes affecting the behaviour of phar-
maceuticals and selected transformation products in relevant
environmental matrices (water, sediment, soil and manure)
will be investigated in a series of laboratory, semi-field and
field studies. Data will be generated on the sorption behav-
iour and persistence of human and veterinary pharma-
ceuticals for a range of environmental conditions (e.g. dif-
ferent soil and sediment characteristics, different microbial
diversity, freshwater vs. marine conditions). The effects of
the application matrix (e.g. manure, sludge) on behaviour
will also be considered. Based on the results of these tests,
recommendations will be provided on experimental ap-
Table 2: Work packages and responsible leaders of work packages within ERAPharm
Environmental risk assessment
Fate & exposure 
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Environmental fate processes Thomas Ternes BfG 
Modelling fate and exposure Kathrin Fenner EAWAG 
Bioanalytical assays for an initial hazard screening and mode of action classification Beate Escher EAWAG 
Impact of antibiotics on environmental microorganisms and development of antimicrobial resistance Heike Schmitt UU 
Impact of pharmaceuticals on terrestrial invertebrates Jörg Römbke ECT 
Impact of pharmaceuticals on aquatic invertebrates Jeanne Garric Cemagref 
Impact of pharmaceuticals on fish: transfer of knowledge from toxicology to ecotoxicology Tom Hutchinson AstraZeneca 
Environmental risk assessment Alistair Boxall UoY 
Co-ordination and project management Thomas Knacker ECT 
 
Fig. 1: Overview of the structure of the project
proaches for assessing the fate of pharmaceuticals as part of
the ERA process. Models for predicting key fate parameters
(e.g. sorption and persistence) will be evaluated and, where
possible, further developed.
A scenario-based exposure assessment system will be devel-
oped for predicting concentrations of human and veterinary
pharmaceuticals in soils, surface waters and sediments as
well as their leaching potential to groundwater. The FOCUS
modelling tools, which are in regulatory use for pesticides,
will be used as a starting point for developing a higher-tier
exposure assessment system for pharmaceuticals. This sys-
tem will consist of a suite of standard scenarios (for charac-
teristically different regions of the EU member and acces-
sion states including Mediterranean and Eastern European
regions) for exposure of the terrestrial and aquatic environ-
ment to pharmaceuticals and a set of adapted, process-based
fate and transport models for soil, surface water and leach-
ing/runoff. The exposure assessment system will be verified
using data generated in the above-mentioned fate studies.
2.2 Effects assessment
ERAPharm will contribute to investigating whether envi-
ronmentally relevant concentrations of human and veteri-
nary pharmaceuticals pose a risk to aquatic and terrestrial
organisms. The project will also improve methods and strat-
egies for assessing the effects of pharmaceuticals. Given the
fact that many pharmaceuticals contain various functional
groups, multiple modes of action can be expected (Escher
& Hermens 2002). Moreover, pharmaceuticals that are of-
ten designed to target specific receptor structures in mam-
mals or in other target organisms such as pathogens and
parasites, may elicit different types of effects in non-target
organisms (Seiler 2002). Due to the lack of knowledge on
these types of effects, test batteries covering many possible
modes of action are required in order to effectively assess the
potential environmental hazard caused by pharmaceuticals.
A good strategy to achieve this is to include species from dif-
ferent taxa and with different reproduction strategies (Sanchez
& Tarazona 2002). Taking this into account, ERAPharm will
improve ecotoxicological test methods in order to detect the
effects of pharmaceuticals from different therapeutic classes
in bacteria, aquatic and terrestrial invertebrates and fish at
different levels of biological organisation (individual, popula-
ERAPharm EU-Projects
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tion, community). The capability of single-species tests to pre-
dict effects at higher levels of biological organisation will be
elucidated by micro-/mesocosm and field studies.
Emphasis will be placed on pharmaceuticals with a specific
mode of action in the environment. Data generated in the
effect work packages will provide the basis for improving
guidance on how to address specific effects (i.e. for target-
ing the effects assessment), for determining relationships
between acute and chronic toxicity and for evaluating the
current fixed environmental concentration action limits that
are used in the ERAs of pharmaceuticals.
A battery of in vitro and low complexity bioanalytical tests
covering relevant modes of action will be used for screening
the pharmaceuticals. The test battery is based on the initial
interactions of the pharmaceuticals with their targets in cells
and on the onset of defence and repair mechanisms in the
cells. The test results will provide a first hazard characteri-
sation and a classification according to the mode(s) of toxic
action. They will be used for targeting the in vivo tests with
invertebrates and fish. In addition, it is planned to screen
degradation products, which have been identified and iso-
lated in the fate studies and/or metabolites.
The impact of human and veterinary antibiotics on the struc-
ture and function of the microbial community will be inves-
tigated for the terrestrial and the aquatic (freshwater and
marine) environment. This aspect has hardly been looked at
in the context of environmental risk assessments, although
the diversity of the microbial community is thought to be
critical to soil health and soil quality (Garbeva 2004). Spe-
cial emphasis will be placed on the potential of antibiotics
to increase genetically-encoded resistance. Different microbial
test systems will be evaluated with regard to their suitability
for inclusion in the ERA procedure for pharmaceuticals.
The effects of human and veterinary pharmaceuticals on ter-
restrial invertebrates will be studied on the laboratory, semi-
field, e.g. terrestrial model ecosystems (Knacker et al. 2004),
and field scale, taking the environmental conditions in dif-
ferent European regions into account. Both structural and
functional endpoints will be considered. A main focus will
be to systematically evaluate the effects of parasiticides on
dung flies and beetles since there is concern about the effects
of these compounds on pasture ecology (Floate et al. 2005).
Effects of human and veterinary pharmaceuticals on aquatic
invertebrates will be investigated considering both exposure
via the water column and exposure via the sediment. While
terrestrial organisms may be exposed locally and temporar-
ily to higher concentrations of pharmaceuticals (e.g. when
veterinary pharmaceuticals such as parasiticides are admin-
istered to grazing animals), aquatic animals are typically
exposed continuously to relatively constant low levels of
pharmaceuticals, especially with regard to human pharma-
ceuticals. Emphasis will thus be placed on life-cycle and
multi-generation tests. In these tests, a broad spectrum of
ecologically-relevant endpoints and indirect effects can be
evaluated. Energy-based models (Péry et al. 2003) will be
used to predict effects at the population level. The impact of
pharmaceuticals will be investigated at the single-species and
microcosm level. In addition, the project will be able to draw
upon long-term mesocosm studies with aquatic invertebrates
that are performed by the Canadian Water Network.
Chronic effects of human pharmaceuticals on fish will be in-
vestigated. As vertebrates with target structures that are often
very similar to those in humans, fish are very likely to be af-
fected by human pharmaceuticals as was demonstrated e.g.
for ethinylestradiol (Larsson et al. 1999). Within ERAPharm,
information from pharmaco- and toxicodynamic studies with
mammalian species and from mechanistic (molecular bio-
logical) studies will be used to supplement fish tests with
additional specific endpoints in order to detect chronic ef-
fects of human pharmaceuticals. It will be evaluated whether
data on pharmaco- and toxicodynamics in mammalian spe-
cies can be used to predict potentially hazardous environ-
mental concentrations and the type of effects to be expected
in fish and in other environmental organisms.
2.3 Environmental risk assessment
The information on fate and effects of pharmaceuticals in
the environment and the improved techniques for determin-
ing exposure and effect concentrations, which have been
generated by the above-mentioned studies, will be used to
propose improvements of existing ERA procedures for hu-
man and veterinary pharmaceuticals (CVMP/VICH 2000
and 2004, EMEA/CHMP 2005). ERAPharm will develop
screening approaches for identifying (1) those substances that
require testing, (2) those environmental compartments and
organisms that are most at risk, and (3) the potential to
bioaccumulate. The results of these approaches can then be
used to target testing. Moreover, PEC action limits and trig-
ger values of the current ERA procedures will be evaluated.
Pragmatic approaches will be developed for evaluating the
risks of transformation products. These approaches will draw
upon current research in the pesticides area, where methods
for assessing fate and effects of transformation products based
on the structure and physico-chemical properties of the trans-
formation product and the parent compound are being devel-
oped (e.g. Fenner et al. 2003, Sinclair & Boxall 2003).
A web-based database with information on fate and effects
of pharmaceuticals will be compiled and a web-based risk
assessment system will be developed. Case studies will be
carried out, i.e. both the newly developed methodologies
and the current ERA approaches will be applied to two se-
lected pharmaceuticals. Based on the results, recommenda-
tions on the environmental risk assessment of human and vet-
erinary pharmaceuticals will be provided that will be made
available to regulators, industry and the scientific community.
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Related projects of the 6th EU framework programme
Project title Acronym Objective Co-ordinator Further information 
Novel methods for integrated 
risk assessment of cumulative 
stressors in Europe 
NoMiracle Development of methods for 
assessing the cumulative risks 
from combined exposures to 
multiple stressors 
Hans Løkke,  
National Environmental 
Research Institute, 
Silkeborg, Denmark 
http://viso.jrc.it/nomiracle 
Models for assessing and 
forecasting the impact of 
environmental key pollutants  
on marine and freshwater 
ecosystems and biodiversity 
MODELKEY Development of predictive 
modelling tools, effect-
assessment and analytical 
methods applicable to 
European freshwater and 
marine ecosystems 
Werner Brack, 
Environmental Research 
Centre (UFZ), Leipzig, 
Germany 
http://www.modelkey.org 
Integrated modelling of the river-
sediment-soil-groundwater 
system; advanced tools for the 
management of catchment 
areas and river basins in the 
context of global change 
Aquaterra Improvement of the scientific 
basis for river basin manage-
ment through a better under-
standing of the river-sediment-
soil-groundwater system 
Peter Grathwohl,  
Eberhard-Karls-University 
Tübingen, Germany 
http://www.eu-aquaterra.de 
 
